

ESC Declaration of Interests Report

2025 ESC Guidelines for the management of cardiovascular disease and pregnancy

All experts contributing to the development of ESC Guidelines must adhere to the *ESC Declaration and Management of Conflicts of Interest Policy*, ensuring transparency and ethical integrity throughout the Guidelines development process.

In accordance with this policy, they are required to submit a yearly Declaration of Interests (DOI). Each DOI undergoes a review based on established policy criteria, as defined in the policy's annex 3, enabling continuous assessment and management of potential conflicts of interest.

For this Guideline, the DOI assessment process began in 2023, evaluating declarations from 2022, and continued in 2024 and 2025—each year including an assessment of interests declared in the preceding calendar year.

Accordingly, for Task Force members, this report includes information declared for years 2022 through 2024. For reviewers, this report includes information declared for years 2023 and 2024.

Experts developing this Guideline have committed to upholding compliance with the policy criteria through 2025, including adherence to a 10,000 EUR threshold for personal payments.

The latest version of the policy and its annexes can be accessed on the ESC website at www.escardio.org/DOI.

2025 ESC Guidelines for the management of cardiovascular disease and pregnancy - TF Members

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2024.

Expert	Type of Relationship with Industry	
Brida Margarita	2022	Nothing to be declared
	2023	Nothing to be declared
	2024	Nothing to be declared
Castelletti Silvia	2022	Nothing to be declared
	2023	Nothing to be declared
	2024	Nothing to be declared
Cauldwell Matthew	2022	Nothing to be declared
	2023	Nothing to be declared
	2024	Nothing to be declared
Cerbai Elisabetta	2022	Nothing to be declared
	2023	Ongoing research funding from public and/or not-for-profit organisations (which started in 2023 or continues in 2023). This information is not mandatory and does not impact one's ability to join an ESC activity European Commission, Italian Minister of research
	2024	Nothing to be declared
Crotti Lia	2022	Nothing to be declared
	2023	Payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc., including travel funding related to these activities. Bristol Myers Squibb : Myocardial Disease
	2024	Payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc., including travel funding related to these activities. Bristol Myers Squibb : Myocardial Disease
De Backer Julie	2022	Membership or affiliation in political or advocacy groups working in the field of cardiology. Member of VASCERN (European Reference Network on Rare Multisystemic Vascular Disease) Any other interest (financial or otherwise) that should be declared in view of holding an ESC position. Member of Clingen Member of the Montalcino Aortic Consortium

2025 ESC Guidelines for the management of cardiovascular disease and pregnancy - TF Members

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2024.

Expert	Type of Relationship with Industry
De Backer Julie	2023 Ongoing research funding from public and/or not-for-profit organisations (which started in 2023 or continues in 2023). This information is not mandatory and does not impact one's ability to join an ESC activity Baillet Latour Funds Funds for Scientific Research Flanders Special Research Fund Ghent University Membership or affiliation in political or advocacy groups working in the field of cardiology. Member of VASCERN (European Reference Network on Rare Multisystemic Vascular Disease) Any other interest (financial or otherwise) that should be declared in view of holding an ESC position (e.g. editorial role in non-ESC publications—editor in chief or other editorial position—and/or officer position in other organisations). Member of Clingen Member of the Montalcino Aortic Consortium Associate Editor for JACC
	2024 Ongoing research funding from public and/or not-for-profit organisations. This information is not mandatory and does not impact one's ability to join an ESC activity Baillet Latour Funds Funds for Scientific Research Flanders Marfan Foundation Special Research Fund Ghent University Membership or affiliation in political or advocacy groups working in the field of cardiovascular medicine. Member of VASCERN (European Reference Network on Rare Multisystemic Vascular Disease) Any other interest (financial or otherwise) that should be declared in view of holding an ESC position (e.g. editorial role in non-ESC publications—editor in chief or other editorial position—and/or officer position in other organisations). Member of Clingen Member of the Montalcino Aortic Consortium Deputy Editor for Circulation: Genomic and Precision Medicine
de Groot Natasja	2022 Payment from healthcare industry to your department or institution or any other body for your personal services: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc. Boston Scientific : Arrhythmias, General Travel and meeting support from healthcare industry, independent of the above activities. atricure, boston scientific : Arrhythmias, General

2025 ESC Guidelines for the management of cardiovascular disease and pregnancy - TF Members

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2024.

Expert	Type of Relationship with Industry	
de Groot Natasja	2023	Payment from healthcare industry to your department or institution or any other body for your personal services: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc., including travel funding related to these activities. Boston Scientific, Atricure, Biosense Webster : Arrhythmias, General Funding from healthcare industry for travel to, and attendance of events and meetings , unrelated to the activities listed in 2.A and 3.A. atricure, boston scientific : Arrhythmias, General
	2024	Nothing to be declared
De Hosson Michele	2022	Nothing to be declared
	2023	Nothing to be declared
	2024	Nothing to be declared
Estensen Mette-Elise	2022	Nothing to be declared
	2023	Nothing to be declared
	2024	Nothing to be declared
Goossens Eva	2022	Nothing to be declared
	2023	Nothing to be declared
	2024	Nothing to be declared
Haring Bernhard	2022	Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc. Edwards Lifesciences : Echocardiography Travel and meeting support from healthcare industry, independent of the above activities. Novartis : Clinical Skills
	2023	Payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc., including travel funding related to these activities. INARI : Echocardiography, Pulmonary Circulation, Pulmonary Embolism, Right Heart Failure

2025 ESC Guidelines for the management of cardiovascular disease and pregnancy - TF Members

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2024.

Expert	Type of Relationship with Industry	
Haring Bernhard	2024	<p>Payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc., including travel funding related to these activities. Boehringer-Ingelheim : Chronic Heart Failure, Risk Factors and Prevention</p> <p>Any other interest (financial or otherwise) that should be declared in view of holding an ESC position (e.g. editorial role in non-ESC publications—editor in chief or other editorial position—and/or officer position in other organisations). I am an assistant editor for the journal "Clinical Research in Cardiology".</p>
Hasselberg Nina Eide	2022	Nothing to be declared
	2023	Nothing to be declared
	2024	Nothing to be declared
Haugaa Kristina Hermann	2022	Nothing to be declared
	2023	<p>Payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc., including travel funding related to these activities. Boehringer-Ingelheim : Myocardial Disease Novartis : Myocardial Disease Bristol Myers Squibb : Myocardial Disease</p>
	2024	<p>Payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc., including travel funding related to these activities. Bristol Myers Squibb : Myocardial Disease Medtronic : Ventricular Arrhythmias and Sudden Cardiac Death (SCD) Solid Bioscience : Ventricular Arrhythmias and Sudden Cardiac Death (SCD)</p> <p>Any other interest (financial or otherwise) that should be declared in view of holding an ESC position (e.g. editorial role in non-ESC publications—editor in chief or other editorial position—and/or officer position in other organisations). Associate guest editor in Circulation Heart failure</p>
Kurpas Donata	2022	Nothing to be declared
	2023	Nothing to be declared
	2024	Nothing to be declared

2025 ESC Guidelines for the management of cardiovascular disease and pregnancy - TF Members

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2024.

Expert	Type of Relationship with Industry	
Mccniery Carmel	2022	Receipt of royalties for intellectual property. Oxford University Press : Hypertension
	2023	Ongoing research funding from public and/or not-for-profit organisations (which started in 2023 or continues in 2023). This information is not mandatory and does not impact one's ability to join an ESC activity Wellcome Receipt of royalties for intellectual property. Oxford University Press : Hypertension Any other interest (financial or otherwise) that should be declared in view of holding an ESC position (e.g. editorial role in non-ESC publications—editor in chief or other editorial position—and/or officer position in other organisations). President - ARTERY Society (Association for Research into Arterial Structure and Physiology)
	2024	Ongoing research funding from public and/or not-for-profit organisations. This information is not mandatory and does not impact one's ability to join an ESC activity Wellcome Any other interest (financial or otherwise) that should be declared in view of holding an ESC position (e.g. editorial role in non-ESC publications—editor in chief or other editorial position—and/or officer position in other organisations). President, ARTERY Society (2023-2025)
Peters Sanne	2022	Nothing to be declared
	2023	Nothing to be declared
	2024	Nothing to be declared
Rakisheva Amina	2022	Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc. Astra Zeneca : Chronic Heart Failure Novartis : Chronic Heart Failure Roche Diagnostics : Chronic Heart Failure

2025 ESC Guidelines for the management of cardiovascular disease and pregnancy - TF Members

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2024.

Expert	Type of Relationship with Industry	
Rakisheva Amina	2023	Payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc., including travel funding related to these activities. Astra Zeneca : Chronic Heart Failure Novartis : Chronic Heart Failure Roche Diagnostics : Chronic Heart Failure
	2024	Payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc., including travel funding related to these activities. Astra Zeneca : Chronic Heart Failure Boehringer-Ingelheim : Chronic Heart Failure
Sambola Antonia	2022	Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc. Organon. : Acute Coronary Syndromes Travel and meeting support from healthcare industry, independent of the above activities. Boehringer-Ingelheim : Acute Coronary Syndromes
	2023	Payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc., including travel funding related to these activities. Boehringer-Ingelheim : Acute Cardiac Care Payment from healthcare industry to your department or institution or any other body for your personal services: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc., including travel funding related to these activities. Daiichi Sankyo : Atrial Fibrillation (AF) Funding from healthcare industry for travel to, and attendance of events and meetings , unrelated to the activities listed in 2.A and 3.A. Rovi : Acute Coronary Syndromes, Acute Cardiac Care

2025 ESC Guidelines for the management of cardiovascular disease and pregnancy - TF Members

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2024.

Expert	Type of Relationship with Industry	
Sambola Antonia	2024	Payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc., including travel funding related to these activities. Astra Zeneca : Acute Coronary Syndromes Daiichi Sankyo : Acute Coronary Syndromes Boehringer-Ingelheim : Atrial Fibrillation (AF) Novartis : Myocardial Disease
Schlager Oliver	2022	Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc. Biotronik : Peripheral Vascular and Cerebrovascular Disease
	2023	Nothing to be declared
	2024	Nothing to be declared
Schoenhoff Florian	2022	Nothing to be declared
	2023	Nothing to be declared
	2024	Any other interest (financial or otherwise) that should be declared in view of holding an ESC position (e.g. editorial role in non-ESC publications—editor in chief or other editorial position—and/or officer position in other organisations). Member of the board of EACTS Chair of the Vascular Domain of EACTS Associate Editor of the EJCTS
Steinbach Francoise	2022	Membership or affiliation in political or advocacy groups working in the field of cardiology. Patient advocate at VASCERN, HTAD WG VP of French Marfan patient organisation Treasurer at Marfan Europe Network
	2023	Membership or affiliation in political or advocacy groups working in the field of cardiology. Patient advocate at VASCERN, HTAD WG VP of French Marfan patient organisation Treasurer at Marfan Europe Network
	2024	Membership or affiliation in political or advocacy groups working in the field of cardiovascular medicine. Patient advocate at VASCERN, HTAD WG Volunteer in the French Marfan patient organisation Treasurer at Marfan Europe Network
Sudano Isabella	2022	Travel and meeting support from healthcare industry, independent of the above activities. Amgen Inc : Risk Factors and Prevention
		Membership or affiliation in political or advocacy groups working in the field of cardiology. Swiss Society of hypertension, Swiss heart Foundation, Swiss Atherosclerosis society, Forum for Tobacco prevention in hospital setting Board Member, all voluntary participation

2025 ESC Guidelines for the management of cardiovascular disease and pregnancy - TF Members

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2024.

Expert	Type of Relationship with Industry
Sudano Isabella	2023 Payment from healthcare industry to your department or institution or any other body for your personal services: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc., including travel funding related to these activities. Amgen : Risk Factors and Prevention Daiichi Sankyo : Risk Factors and Prevention Novartis : Risk Factors and Prevention Sanofi Aventis : Risk Factors and Prevention Recor Medical : Risk Factors and Prevention Membership or affiliation in political or advocacy groups working in the field of cardiology. Swiss Society of hypertension, Swiss heart Foundation, Swiss Atheosclerosis society, Forum for Tobacco prevention in hospital setting Board Member, all voluntary participation
	2024 Payment from healthcare industry to your department or institution or any other body for your personal services: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc., including travel funding related to these activities. Amgen : Risk Factors and Prevention Daiichi Sankyo : Risk Factors and Prevention Novartis : Risk Factors and Prevention Sanofi Aventis : Risk Factors and Prevention Recor Medical : Risk Factors and Prevention Membership or affiliation in political or advocacy groups working in the field of cardiovascular medicine. Swiss Society of hypertension, Swiss heart Foundation, Swiss Atheosclerosis society, Forum for Tobacco prevention in hospital setting Board Member, all voluntary participation
Swan Lorna	2022 Membership or affiliation in political or advocacy groups working in the field of cardiology. International Society of Adult Congenital Heart Disease - Education Co-lead
	2023 Membership or affiliation in political or advocacy groups working in the field of cardiology. Member of ISACHD (international society of ACHD)
	2024 Membership or affiliation in political or advocacy groups working in the field of cardiovascular medicine. Member of ISACHD (international society of ACHD)

2025 ESC Guidelines for the management of cardiovascular disease and pregnancy - TF Members

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2024.

Expert	Type of Relationship with Industry
Tommaso Simoncini	2022 Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc. Abbott : Nuclear Imaging, Other Shionogi : Other Intuitive : Other Applied Medical : Other Theramex : Other
	2023 Payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc., including travel funding related to these activities. Abbott : Other Astellas : Other
	2024 Payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc., including travel funding related to these activities. Abbott : Other Payment from healthcare industry to your department or institution or any other body for your personal services: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc., including travel funding related to these activities. Bayer : Other
Valente Anne Marie	2022 Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc. Elsevier : Congenital Heart Disease and Paediatric Cardiology
	2023 Payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc., including travel funding related to these activities. Elsevier : Congenital Heart Disease and Paediatric Cardiology
	2024 Payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc., including travel funding related to these activities. Elsevier : Congenital Heart Disease and Paediatric Cardiology

2025 ESC Guidelines for the management of cardiovascular disease and pregnancy - Review panel

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2024.

Expert	Type of Relationship with Industry	
Abilova Saamai	2023	Nothing to be declared
	2024	Nothing to be declared
Adamo Marianna	2023	Payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc., including travel funding related to these activities. Edwards Lifesciences : Valvular Heart Disease Abbott Vascular : Valvular Heart Disease
	2024	Payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc., including travel funding related to these activities. Edwards Lifesciences : Valvular Heart Disease Abbott Vascular : Valvular Heart Disease
Adamson Dawn Louise	2023	Funding from healthcare industry for travel to, and attendance of events and meetings , unrelated to the activities listed in 2.A and 3.A. Medtronic : Interventional Cardiology Membership or affiliation in political or advocacy groups working in the field of cardiology. I am the National Speciality Advisor for Cardiology for NHS England
	2024	Membership or affiliation in political or advocacy groups working in the field of cardiovascular medicine. I am the National Speciality Advisor for Cardiology for NHS England I am the President of the UK Maternal cardiac society, an affiliate of the British Cardiovascular society and thus sit on their board.
Aghayeva Gulane	2023	Nothing to be declared
	2024	Nothing to be declared
Arat Ozkan Alev	2023	Payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc., including travel funding related to these activities. Sanofi Aventis : Cardiovascular Disease in Special Populations Servier : Coronary Artery Disease (Chronic) / Chronic Coronary Syndromes (CCS)
	2024	Nothing to be declared

2025 ESC Guidelines for the management of cardiovascular disease and pregnancy - Review panel

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2024.

Expert	Type of Relationship with Industry	
Arbelo Elena	2023	<p>Ongoing research funding from public and/or not-for-profit organisations (which started in 2023 or continues in 2023). This information is not mandatory and does not impact one's ability to join an ESC activity Marató TV3</p> <p>Payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc., including travel funding related to these activities. Bayer : Atrial Fibrillation (AF) Biosense Webster : Atrial Fibrillation (AF)</p>
	2024	<p>Payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc., including travel funding related to these activities. Boston Scientific : Arrhythmias, General Bristol Myers Squibb : Myocardial Disease Medtronic : Ventricular Arrhythmias and Sudden Cardiac Death (SCD)</p> <p>Membership or affiliation in political or advocacy groups working in the field of cardiovascular medicine. Chair of the EHRA Advocacy, Quality improvement and Health Economics Committee Member of the ESC Advocacy Committee</p>
Arbustini Eloisa	2023	<p>Ongoing research funding from public and/or not-for-profit organisations (which started in 2023 or continues in 2023). This information is not mandatory and does not impact one's ability to join an ESC activity Italian Ministry of Health</p>
	2024	<p>Ongoing research funding from public and/or not-for-profit organisations. This information is not mandatory and does not impact one's ability to join an ESC activity Italian Ministry of Health</p>
Balint Hajnalka	2023	Nothing to be declared
	2024	<p>Payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc., including travel funding related to these activities. MSD : Pulmonary Circulation, Pulmonary Embolism, Right Heart Failure</p>
Barakat Elias	2023	Nothing to be declared
	2024	Nothing to be declared

2025 ESC Guidelines for the management of cardiovascular disease and pregnancy - Review panel

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2024.

Expert	Type of Relationship with Industry	
Barysiene Jurate	2023	Payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc., including travel funding related to these activities. Bayer : Atrial Fibrillation (AF) Pfizer : Atrial Fibrillation (AF) Servier : Atrial Fibrillation (AF)
	2024	Payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc., including travel funding related to these activities. Servier : Atrial Fibrillation (AF)
Benyass Aatif	2023	Payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc., including travel funding related to these activities. Astra Zeneca : Chronic Heart Failure Boehringer-Ingelheim : Chronic Heart Failure Novartis : Chronic Heart Failure
	2024	Payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc., including travel funding related to these activities. Astra Zeneca : Chronic Heart Failure Boehringer-Ingelheim : Chronic Heart Failure Novartis : Chronic Heart Failure
Boriani Giuseppe	2023	Nothing to be declared
	2024	Payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc., including travel funding related to these activities. Bristol Myers Squibb : Arrhythmias, General Daiichi Sankyo : Atrial Fibrillation (AF) Boston Scientific : Ventricular Arrhythmias and Sudden Cardiac Death (SCD) Any other interest (financial or otherwise) that should be declared in view of holding an ESC position (e.g. editorial role in non-ESC publications—editor in chief or other editorial position—and/or officer position in other organisations). Member of the Editorial Board of Acta Cardiologica and European Journal of Internal Medicine
Bosevski Marijan	2023	Nothing to be declared

2025 ESC Guidelines for the management of cardiovascular disease and pregnancy - Review panel

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2024.

Expert	Type of Relationship with Industry	
Bosevski Marijan	2024	Nothing to be declared
Brennan Paul	2023	Nothing to be declared
	2024	Funding from healthcare industry for travel to, and attendance of events and meetings , unrelated to the activities listed in 2.A and 3.A. Edwards Lifesciences : Interventional Cardiology
Brucato Antonio	2023	Ongoing research funding from public and/or not-for-profit organisations (which started in 2023 or continues in 2023). This information is not mandatory and does not impact one's ability to join an ESC activity CARIPLO Cassa di Risparmio Province Lombarde Research funding from healthcare industry received by your department/institution or an entity controlled by your department/institution , under your direct/personal responsibility. SOBI : to analyse inflammasome activation in pericardial fluid in acute pericarditis and chronic pericardial effusions, chief investigator
	2024	Ongoing research funding from public and/or not-for-profit organisations. This information is not mandatory and does not impact one's ability to join an ESC activity CARIPLO Cassa di Risparmio Province Lombarde Research funding from healthcare industry received by your department/institution or an entity controlled by your department/institution , under your direct/personal responsibility. SOBI : to analyse inflammasome activation in pericardial fluid in acute pericarditis and chronic pericardial effusions, chief investigator Kiniksa : unrestricted research grant to support a data manager, chief investigator
Buccheri Sergio	2023	Nothing to be declared
	2024	Funding from healthcare industry for travel to, and attendance of events and meetings , unrelated to the activities listed in 2.A and 3.A. Abbott : Valvular Heart Disease

2025 ESC Guidelines for the management of cardiovascular disease and pregnancy - Review panel

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2024.

Expert	Type of Relationship with Industry
Budts Werner	2023 Payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc., including travel funding related to these activities. Occlutech : Congenital Heart Disease and Paediatric Cardiology Payment from healthcare industry to your department or institution or any other body for your personal services: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc., including travel funding related to these activities. Janssen-Cilag : Congenital Heart Disease and Paediatric Cardiology Medtronic : Congenital Heart Disease and Paediatric Cardiology Occlutech : Congenital Heart Disease and Paediatric Cardiology St Jude Medical Abbott : Congenital Heart Disease and Paediatric Cardiology
	2024 Payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc., including travel funding related to these activities. Occlutech : Congenital Heart Disease and Paediatric Cardiology Payment from healthcare industry to your department or institution or any other body for your personal services: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc., including travel funding related to these activities. Janssen-Cilag : Congenital Heart Disease and Paediatric Cardiology Medtronic : Congenital Heart Disease and Paediatric Cardiology Occlutech : Congenital Heart Disease and Paediatric Cardiology St Jude Medical Abbott : Congenital Heart Disease and Paediatric Cardiology
Bugagis Hanan	2023 Nothing to be declared
	2024 Nothing to be declared
Bura Riviere Alessandra	2023 Payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc., including travel funding related to these activities. BMS : Pulmonary Circulation, Pulmonary Embolism, Right Heart Failure Bayer : Pulmonary Circulation, Pulmonary Embolism, Right Heart Failure, Peripheral Vascular and Cerebrovascular Disease

2025 ESC Guidelines for the management of cardiovascular disease and pregnancy - Review panel

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2024.

Expert	Type of Relationship with Industry	
Bura Riviere Alessandra	2024	Payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc., including travel funding related to these activities. BMS : Pulmonary Circulation, Pulmonary Embolism, Right Heart Failure Bayer : Pulmonary Circulation, Pulmonary Embolism, Right Heart Failure, Peripheral Vascular and Cerebrovascular Disease
Calda Pavel	2023	Research funding from healthcare industry received personally by you or an entity controlled by you. Kedrion
	2024	Nothing to be declared
Caruana Maryanne	2023	Membership or affiliation in political or advocacy groups working in the field of cardiology. Chairperson, Beating Hearts Malta - voluntary organisation for children and adults with congenital heart disease in Malta Any other interest (financial or otherwise) that should be declared in view of holding an ESC position (e.g. editorial role in non-ESC publications—editor in chief or other editorial position—and/or officer position in other organisations). Associate Editor, General Cardiovascular Medicine for Frontiers in Cardiovascular Medicine since September 2023
	2024	Funding from healthcare industry for travel to, and attendance of events and meetings , unrelated to the activities listed in 2.A and 3.A. Menarini : Chronic Heart Failure, Acute Heart Failure Membership or affiliation in political or advocacy groups working in the field of cardiovascular medicine. Chairperson of Beating Hearts Malta, a non-profit organisation in Malta that works with children and adults with congenital heart disease and their families Any other interest (financial or otherwise) that should be declared in view of holding an ESC position (e.g. editorial role in non-ESC publications—editor in chief or other editorial position—and/or officer position in other organisations). Associate Editor for Frontiers in Cardiovascular Medicine (General Cardiovascular Medicine)
Christersson Christina	2023	Payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc., including travel funding related to these activities. Astra Zeneca : Chronic Heart Failure Bristol Myers Squibb : Chronic Heart Failure Pfizer : Valvular Heart Disease
	2024	Payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc., including travel funding related to these activities. Pfizer : Valvular Heart Disease

2025 ESC Guidelines for the management of cardiovascular disease and pregnancy - Review panel

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2024.

Expert	Type of Relationship with Industry
Dan Gheorghe Andrei	2023 Payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc., including travel funding related to these activities. Bayer : Atrial Fibrillation (AF) Berlin Chemie AG : Atrial Fibrillation (AF) Boehringer-Ingelheim : Atrial Fibrillation (AF), Chronic Heart Failure Krka Pharma : Pharmacology and Pharmacotherapy Novartis : Risk Factors and Prevention Sanofi Aventis : Risk Factors and Prevention Funding from healthcare industry for travel to, and attendance of events and meetings , unrelated to the activities listed in 2.A and 3.A. Berlin Chemie AG : European Society of Cardiology Membership or affiliation in political or advocacy groups working in the field of cardiology. Member of the Cardiology Consultant Commission of the Health Ministry, Romania
	2024 Payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc., including travel funding related to these activities. Berlin Chemie AG : Atrial Fibrillation (AF) Krka Pharma : Pharmacology and Pharmacotherapy Novartis : Risk Factors and Prevention Funding from healthcare industry for travel to, and attendance of events and meetings , unrelated to the activities listed in 2.A and 3.A. Berlin Chemie AG : European Society of Cardiology Membership or affiliation in political or advocacy groups working in the field of cardiovascular medicine. Member of the Cardiology Consultant Commission of the Health Ministry, Romania
David Lilia	2023 Nothing to be declared
	2024 Nothing to be declared
Demiraj Aurel	2023 Nothing to be declared
	2024 Nothing to be declared

2025 ESC Guidelines for the management of cardiovascular disease and pregnancy - Review panel

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2024.

Expert	Type of Relationship with Industry
Dimopoulos Konstantinos	2023 Payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc., including travel funding related to these activities. Janssen-Cilag : Pulmonary Circulation, Pulmonary Embolism, Right Heart Failure Funding from healthcare industry for travel to, and attendance of events and meetings , unrelated to the activities listed in 2.A and 3.A. Janssen-Cilag : Pulmonary Circulation, Pulmonary Embolism, Right Heart Failure Research funding from healthcare industry received by your department/institution or an entity controlled by your department/institution , under your direct/personal responsibility. Janssen-Cilag : PhD Fellowship, Principal supervisor
	2024 Research funding from healthcare industry received by your department/institution or an entity controlled by your department/institution , under your direct/personal responsibility. Janssen-Cilag : PhD in Pulmonary Hypertension Associated with Congenital Heart Disease, PhD supervisor, CI Any other interest (financial or otherwise) that should be declared in view of holding an ESC position (e.g. editorial role in non-ESC publications—editor in chief or other editorial position—and/or officer position in other organisations). Member of the Writing Committee of the AHA/ACC guidelines 2025 Editorial board (associate editor of IJC and IJC-CHD)
Driss Meriem	2023 Nothing to be declared
	2024 Nothing to be declared
Dubrava Juraj	2023 Payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc., including travel funding related to these activities. Boehringer-Ingelheim : Chronic Heart Failure
	2024 Nothing to be declared
Egidio Assenza Gabriele	2023 Ongoing research funding from public and/or not-for-profit organisations (which started in 2023 or continues in 2023). This information is not mandatory and does not impact one's ability to join an ESC activity Italian Minister of Health, DI_SOUND Study Funding from healthcare industry for travel to, and attendance of events and meetings , unrelated to the activities listed in 2.A and 3.A. Edwards Lifesciences : Valvular Heart Disease

2025 ESC Guidelines for the management of cardiovascular disease and pregnancy - Review panel

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2024.

Expert	Type of Relationship with Industry
Egidy Assenza Gabriele	<p>2024</p> <p>Ongoing research funding from public and/or not-for-profit organisations. This information is not mandatory and does not impact one's ability to join an ESC activity Italian Minister of Health, DI_SOUND Study</p> <p>Funding from healthcare industry for travel to, and attendance of events and meetings , unrelated to the activities listed in 2.A and 3.A. Edwards Lifesciences : Valvular Heart Disease</p>
Egorova Anastasia	<p>2023</p> <p>Payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc., including travel funding related to these activities. Boston Scientific : Device Therapy, Chronic Heart Failure, e-Cardiology/Digital Health Medtronic Foundation : Device Therapy, e-Cardiology/Digital Health</p> <p>2024</p> <p>Payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc., including travel funding related to these activities. Abbott : Device Therapy Boston Scientific : Device Therapy, Chronic Heart Failure, e-Cardiology/Digital Health Medtronic Foundation : Device Therapy, e-Cardiology/Digital Health</p>
Fichtner Stephanie	<p>2023</p> <p>Payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc., including travel funding related to these activities. Daiichi Sankyo : Atrial Fibrillation (AF) Pfizer : Atrial Fibrillation (AF) Biotronik : Device Therapy</p> <p>Membership or affiliation in political or advocacy groups working in the field of cardiology. DGK (German cardiac association EHRA (european heart rhythm association))</p> <p>2024</p> <p>Payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc., including travel funding related to these activities. Astra Zeneca : Atrial Fibrillation (AF) Biotronik : Device Therapy</p> <p>Membership or affiliation in political or advocacy groups working in the field of cardiovascular medicine. DGK (German society of cardiology) ESC EHRA</p>

2025 ESC Guidelines for the management of cardiovascular disease and pregnancy - Review panel

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2024.

Expert	Type of Relationship with Industry
Frogoudaki Alexandra	2023 Funding from healthcare industry for travel to, and attendance of events and meetings , unrelated to the activities listed in 2.A and 3.A. Pfizer : Atrial Fibrillation (AF) ELPEN : Chronic Heart Failure, Coronary Artery Disease (Chronic) / Chronic Coronary Syndromes (CCS), Hypertension Recordati International : Hypertension
	2024 Funding from healthcare industry for travel to, and attendance of events and meetings , unrelated to the activities listed in 2.A and 3.A. ELPEN : Chronic Heart Failure, Coronary Artery Disease (Chronic) / Chronic Coronary Syndromes (CCS), Hypertension Genesis Pharma : Myocardial Disease, Chronic Heart Failure
Gandjbakhch Estelle	2023 Payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc., including travel funding related to these activities. Boston Scientific : Device Therapy Medtronic : Device Therapy Biotronik : Device Therapy Microport : Device Therapy Abbott : Interventional Cardiology Research funding from healthcare industry received by your department/institution or an entity controlled by your department/institution , under your direct/personal responsibility. Biotronik : research grant for academic research on inherited arrhythmia and catheter ablation, investigator Boston Scientific : research grant for academic research on inherited arrhythmia and catheter ablation, principal investigator Medtronic : research grant for academic research on inherited arrhythmia and catheter ablation, principal investigator Microport : research grant for academic research on inherited arrhythmia and catheter ablation, principal investigator

2025 ESC Guidelines for the management of cardiovascular disease and pregnancy - Review panel

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2024.

Expert	Type of Relationship with Industry
Gandjbakhch Estelle	<p>2024</p> <p>Payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc., including travel funding related to these activities. Boston Scientific : Device Therapy Medtronic : Device Therapy Biotronik : Device Therapy Zoll Medical : Device Therapy Microport : Device Therapy Abbott : Interventional Cardiology Tenaya : Myocardial Disease</p> <p>Research funding from healthcare industry received by your department/institution or an entity controlled by your department/institution , under your direct/personal responsibility. Biotronik : research grant for academic research on inherited arrhythmia and catheter ablation, investigator Boston Scientific : research grant for academic research on inherited arrhythmia and catheter ablation, principal investigator Medtronic : research grant for academic research on inherited arrhythmia and catheter ablation, principal investigator Microport : research grant for academic research on inherited arrhythmia and catheter ablation, principal investigator</p>
Gerdts Eva	<p>2023</p> <p>Payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc., including travel funding related to these activities. Astellas : Other</p> <p>Any other interest (financial or otherwise) that should be declared in view of holding an ESC position (e.g. editorial role in non-ESC publications—editor in chief or other editorial position—and/or officer position in other organisations). I am member of the editorial boards of the journals Blood Pressure and High Blood Pressure and Cardiovascular Prevention.</p> <p>2024</p> <p>Payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc., including travel funding related to these activities. Boehringer-Ingelheim : Chronic Heart Failure</p> <p>Any other interest (financial or otherwise) that should be declared in view of holding an ESC position (e.g. editorial role in non-ESC publications—editor in chief or other editorial position—and/or officer position in other organisations). I am member of the editorial boards of the journals Blood Pressure and High Blood Pressure and Cardiovascular Prevention.</p>
Gevaert Sofie	<p>2023</p> <p>Nothing to be declared</p>

2025 ESC Guidelines for the management of cardiovascular disease and pregnancy - Review panel

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2024.

Expert	Type of Relationship with Industry	
Gevaert Sofie	2024	Payment from healthcare industry to your department or institution or any other body for your personal services: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc., including travel funding related to these activities. Boehringer-Ingelheim : Acute Heart Failure
Gigante Bruna	2023	Nothing to be declared
	2024	Ongoing research funding from public and/or not-for-profit organisations. This information is not mandatory and does not impact one's ability to join an ESC activity Swedish Heart and Lung foundation Swedish Research Council Membership or affiliation in political or advocacy groups working in the field of cardiovascular medicine. Chair Elect WG on Thrombosis
Gluhovic Milan	2023	Payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc., including travel funding related to these activities. Berlin Menarini : Clinical Skills Nobel : Echocardiography Farmavita : European Society of Cardiology Bosnalijek : Other Salvus : Risk Factors and Prevention Novartis : Training and Education Krka Pharma : Training and Education Alcaloid AD Skopje : Training and Education Hemofarm : Training and Education

2025 ESC Guidelines for the management of cardiovascular disease and pregnancy - Review panel

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2024.

Expert	Type of Relationship with Industry
Gluhovic Milan	2024 Payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc., including travel funding related to these activities. Astra Zeneca : Clinical Skills Servier : Clinical Skills Lek : Clinical Skills Berlin Menarini : Clinical Skills Amsal BiH : Clinical Skills Nobel : Echocardiography Farmavita : European Society of Cardiology Bosnalijek : Other Salvus : Risk Factors and Prevention Novartis : Training and Education Krka Pharma : Training and Education Alcaloid AD Skopje : Training and Education Hemofarm : Training and Education
Gotcheva Nina	2023 Payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc., including travel funding related to these activities. Boehringer-Ingelheim : Chronic Heart Failure Payment from healthcare industry to your department or institution or any other body for your personal services: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc., including travel funding related to these activities. Boehringer-Ingelheim : Chronic Heart Failure

2025 ESC Guidelines for the management of cardiovascular disease and pregnancy - Review panel

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2024.

Expert	Type of Relationship with Industry
Gotcheva Nina	<p>2024 Payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc., including travel funding related to these activities. Boehringer-Ingelheim : Chronic Heart Failure, Acute Coronary Syndromes, Coronary Artery Disease (Chronic) / Chronic Coronary Syndromes (CCS)</p> <p>Payment from healthcare industry to your department or institution or any other body for your personal services: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc., including travel funding related to these activities. Boehringer-Ingelheim : Chronic Heart Failure, Acute Coronary Syndromes</p>
Greutmann Matthias	<p>2023 Nothing to be declared</p> <p>2024 Nothing to be declared</p>
Guldbrand Dorte	<p>2023 Nothing to be declared</p> <p>2024 Nothing to be declared</p>
Hayrapetyan Hamlet	<p>2023 Payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc., including travel funding related to these activities. Servier : Hypertension Gedeon Richter : Hypertension Egis Pharma : Risk Factors and Prevention</p> <p>Research funding from healthcare industry received by your department/institution or an entity controlled by your department/institution , under your direct/personal responsibility. Servier : RCT, national coordinator</p> <p>2024 Payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc., including travel funding related to these activities. Servier : Hypertension Egis Pharma : Risk Factors and Prevention Krka Pharma : Risk Factors and Prevention</p> <p>Research funding from healthcare industry received by your department/institution or an entity controlled by your department/institution , under your direct/personal responsibility. Acino : Multicenter International Study, Principal Investigator Servier : RCT, Principal investigator</p>

2025 ESC Guidelines for the management of cardiovascular disease and pregnancy - Review panel

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2024.

Expert	Type of Relationship with Industry	
Heidecker Bettina	2023	<p>Ongoing research funding from public and/or not-for-profit organisations (which started in 2023 or continues in 2023). This information is not mandatory and does not impact one's ability to join an ESC activity Pfizer</p> <p>Payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc., including travel funding related to these activities. Pfizer, Bayer, Sanofi-Aventis, Novartis, Astra Zeneca : Clinical Skills, Chronic Heart Failure, Acute Heart Failure, Myocardial Disease, Pericardial Disease</p> <p>Research funding from healthcare industry received by your department/institution or an entity controlled by your department/institution , under your direct/personal responsibility. Pfizer : Analysis of biomarkers in blood of patients with amyloidosis; assess risk for adverse cardiovascular events, Principal investigator</p>
	2024	<p>Ongoing research funding from public and/or not-for-profit organisations. This information is not mandatory and does not impact one's ability to join an ESC activity Pfizer</p> <p>Payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc., including travel funding related to these activities. Pfizer, Bayer, Sanofi-Aventis, Novartis, Astra Zeneca : Clinical Skills , Chronic Heart Failure , Acute Heart Failure , Myocardial Disease , Pericardial Disease</p> <p>Research funding from healthcare industry received by your department/institution or an entity controlled by your department/institution , under your direct/personal responsibility. Pfizer : Analysis of biomarkers in blood of patients with amyloidosis; assess risk for adverse cardiovascular events, Principal investigator</p>
Henine Nora	2023	Nothing to be declared
	2024	Nothing to be declared
Hrafnkelsdottir Thordis	2023	<p>Payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc., including travel funding related to these activities. Astra Zeneca : Chronic Heart Failure</p>
	2024	<p>Payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc., including travel funding related to these activities. Pfizer : Chronic Heart Failure, Acute Heart Failure</p> <p>Novartis : Coronary Artery Disease (Chronic) / Chronic Coronary Syndromes (CCS), Risk Factors and Prevention</p> <p>Astra Zeneca : Training and Education</p>

2025 ESC Guidelines for the management of cardiovascular disease and pregnancy - Review panel

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2024.

Expert	Type of Relationship with Industry	
Ibanez Borja	2023	Any other interest (financial or otherwise) that should be declared in view of holding an ESC position (e.g. editorial role in non-ESC publications—editor in chief or other editorial position—and/or officer position in other organisations). My center (CNIC) is a public non-profit institution that receives Royalties for the sale of a polypill containing aspirin, ramipril and atorvastatin (trinomia, sincronium). I am not involved in the development I do NOT receive any personal benefit (neither direct nor indirect).
	2024	Any other interest (financial or otherwise) that should be declared in view of holding an ESC position (e.g. editorial role in non-ESC publications—editor in chief or other editorial position—and/or officer position in other organisations). My center (CNIC) is a public non-profit institution that receives Royalties for the sale of a polypill containing aspirin, ramipril and atorvastatin (trinomia, sincronium). I am not involved in the development I do NOT receive any personal benefit (neither direct nor indirect).
Ibrahimi Pranvera	2023	Nothing to be declared
	2024	Nothing to be declared
Ilhao Moreira Rita	2023	Nothing to be declared
	2024	Nothing to be declared
Ilic Aleksandra	2023	Payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc., including travel funding related to these activities. Galenica Vifor : Atrial Fibrillation (AF) Boehringer-Ingelheim : Chronic Heart Failure Novartis : Chronic Heart Failure Astrazeneca : Chronic Heart Failure Servier : Hypertension Krka Pharma : Hypertension PharmaSwiss : Risk Factors and Prevention Viartis : Risk Factors and Prevention Funding from healthcare industry for travel to, and attendance of events and meetings , unrelated to the activities listed in 2.A and 3.A. GE Healthcare : Echocardiography

2025 ESC Guidelines for the management of cardiovascular disease and pregnancy - Review panel

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2024.

Expert	Type of Relationship with Industry
Ilic Aleksandra	2024 Payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc., including travel funding related to these activities. Boehringer-Ingelheim : Chronic Heart Failure Novartis : Chronic Heart Failure Astrazeneca : Chronic Heart Failure Servier : Hypertension Krka Pharma : Hypertension PharmaSwiss : Risk Factors and Prevention Viartis : Risk Factors and Prevention
Iung Bernard	2023 Ongoing research funding from public and/or not-for-profit organisations (which started in 2023 or continues in 2023). This information is not mandatory and does not impact one's ability to join an ESC activity Agence nationale de la recherche : Reseach projet RHU STOP AS on aortic stenosis, Work package leader, (ref. e ANR-16-RHU-0003-STOP-AS) Any other interest (financial or otherwise) that should be declared in view of holding an ESC position (e.g. editorial role in non-ESC publications—editor in chief or other editorial position—and/or officer position in other organisations). President of the French Society of Cardiology Deputy Editor of the Archives of Cardiovascular Diseases Guest Editor of Circulation <hr/> 2024 Ongoing research funding from public and/or not-for-profit organisations. This information is not mandatory and does not impact one's ability to join an ESC activity Agence nationale de la recherche : Reseach projet RHU STOP AS on aortic stenosis, Work package leader, (ref. e ANR-16-RHU-0003-STOP-AS) Any other interest (financial or otherwise) that should be declared in view of holding an ESC position (e.g. editorial role in non-ESC publications—editor in chief or other editorial position—and/or officer position in other organisations). President of the French Society of Cardiology Deputy Editor of the Archives of Cardiovascular Diseases Guest Editor of Circulation
Jalabadze Khatuna	2023 Nothing to be declared <hr/> 2024 Nothing to be declared

2025 ESC Guidelines for the management of cardiovascular disease and pregnancy - Review panel

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2024.

Expert	Type of Relationship with Industry
James Stefan	<p>2023</p> <p>Ongoing research funding from public and/or not-for-profit organisations (which started in 2023 or continues in 2023). This information is not mandatory and does not impact one's ability to join an ESC activity Wallenberg foundation, Swedish heart and lung foundation</p> <p>Payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc., including travel funding related to these activities. Medtronic : Valvular Heart Disease</p> <p>Research funding from healthcare industry received by your department/institution or an entity controlled by your department/institution , under your direct/personal responsibility. Elixir : clinical trial, study chair MSD : Clinical trial, trial executive committee Amgen : Executive committee member, Executive committee member Janssen-Cilag : Executive committee member, Executive committee member Astra Zeneca : Study PI , Principal investigator</p> <p>Membership or affiliation in political or advocacy groups working in the field of cardiology. Swedish medical Association, Swedish cardiac society</p>
	<p>2024</p> <p>Ongoing research funding from public and/or not-for-profit organisations. This information is not mandatory and does not impact one's ability to join an ESC activity Swedish research council</p> <p>Payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc., including travel funding related to these activities. Edwards Lifesciences : Valvular Heart Disease Medtronic : Valvular Heart Disease</p> <p>Research funding from healthcare industry received by your department/institution or an entity controlled by your department/institution , under your direct/personal responsibility. Amgen Inc : Clinical trial, Executive committee Merck Sharp & Dohme : Clinical trial, Executive committee New Amsterdam : DSMB committee. Lipid management , DSMB committee Janssen-Cilag : Executive committee, Executive committee</p>

2025 ESC Guidelines for the management of cardiovascular disease and pregnancy - Review panel

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2024.

Expert	Type of Relationship with Industry	
James Stefan	2024	Membership or affiliation in political or advocacy groups working in the field of cardiovascular medicine. Board member of the Swedish research council
Johnson Mark	2023	Ongoing research funding from public and/or not-for-profit organisations (which started in 2023 or continues in 2023). This information is not mandatory and does not impact one's ability to join an ESC activity Borne Foundation Research funding from healthcare industry received by your department/institution or an entity controlled by your department/institution , under your direct/personal responsibility. Nordic Pharma : Induction of labour study, Chief Investigator
	2024	Ongoing research funding from public and/or not-for-profit organisations. This information is not mandatory and does not impact one's ability to join an ESC activity Borne Foundation Research funding from healthcare industry received by your department/institution or an entity controlled by your department/institution , under your direct/personal responsibility. Nordic Pharma : Induction of labour study, Chief Investigator
Juni Peter	2023	Nothing to be declared
	2024	Nothing to be declared
Junusbekova Gulnara	2023	Payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc., including travel funding related to these activities. Abbott : Hypertension Servier : Hypertension
	2024	Payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc., including travel funding related to these activities. Astra Zeneca : Chronic Heart Failure Boehringer-Ingelheim : Chronic Heart Failure Abbott : Hypertension Servier : Hypertension Krka Pharma : Hypertension

2025 ESC Guidelines for the management of cardiovascular disease and pregnancy - Review panel

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2024.

Expert	Type of Relationship with Industry
Jurcut Ruxandra Oana	<p>2023</p> <p>Payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc., including travel funding related to these activities. Pfizer : Atrial Fibrillation (AF), Myocardial Disease, Pulmonary Circulation, Pulmonary Embolism, Right Heart Failure Astra Zeneca : Chronic Heart Failure Novartis : Chronic Heart Failure Servier : Hypertension Genzyme : Myocardial Disease Genesys : Myocardial Disease Bayer AG : Other</p> <p>Funding from healthcare industry for travel to, and attendance of events and meetings , unrelated to the activities listed in 2.A and 3.A. Pfizer : Training and Education</p> <p>Research funding from healthcare industry received by your department/institution or an entity controlled by your department/institution , under your direct/personal responsibility. Pfizer : Global Medical Grants Pfizer - ATTR amyloidosis, Principal investigator</p>

2025 ESC Guidelines for the management of cardiovascular disease and pregnancy - Review panel

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2024.

Expert	Type of Relationship with Industry
Jurcut Ruxandra Oana	2024 Payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc., including travel funding related to these activities. Pfizer : Atrial Fibrillation (AF), Myocardial Disease, Pulmonary Circulation, Pulmonary Embolism, Right Heart Failure Astra Zeneca : Chronic Heart Failure Novartis : Chronic Heart Failure Servier : Hypertension Genzyme : Myocardial Disease Genesys : Myocardial Disease Bayer AG : Other Funding from healthcare industry for travel to, and attendance of events and meetings , unrelated to the activities listed in 2.A and 3.A. Pfizer : Training and Education Research funding from healthcare industry received by your department/institution or an entity controlled by your department/institution , under your direct/personal responsibility. Pfizer : Global Medical Grants Pfizer - ATTR amyloidosis, Principal investigator
Kalejs Oskars	2023 Payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc., including travel funding related to these activities. Boehringer-Ingelheim : Atrial Fibrillation (AF) Astra Zeneca : Chronic Heart Failure Servier : Chronic Heart Failure Bayer AG : Stroke <hr/> 2024 Payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc., including travel funding related to these activities. Boehringer-Ingelheim : Atrial Fibrillation (AF) Astra Zeneca : Chronic Heart Failure Servier : Chronic Heart Failure Bayer AG : Stroke
Karakiriou Maria	2023 Nothing to be declared

2025 ESC Guidelines for the management of cardiovascular disease and pregnancy - Review panel

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2024.

Expert	Type of Relationship with Industry	
Karakiriou Maria	2024	Nothing to be declared
Kluin Jolanda	2023	Payment from healthcare industry to your department or institution or any other body for your personal services: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc., including travel funding related to these activities. Medela : Other Medtronic : Training and Education
	2024	Nothing to be declared
Kober Lars	2023	Payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc., including travel funding related to these activities. Astra Zeneca : Chronic Heart Failure Boehringer-Ingelheim : Chronic Heart Failure Novartis : Chronic Heart Failure Novo-Nordisk : Chronic Heart Failure
	2024	Payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc., including travel funding related to these activities. Astra Zeneca : Chronic Heart Failure Boehringer-Ingelheim : Chronic Heart Failure Novartis : Chronic Heart Failure Novo-Nordisk : Chronic Heart Failure
Koskinas Konstantinos	2023	Payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc., including travel funding related to these activities. Amgen : Risk Factors and Prevention Daiichi Sankyo : Risk Factors and Prevention Sanofi Aventis : Risk Factors and Prevention

2025 ESC Guidelines for the management of cardiovascular disease and pregnancy - Review panel

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2024.

Expert	Type of Relationship with Industry
Koskinas Konstantinos	<p>2024</p> <p>Payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc., including travel funding related to these activities. Sanofi Aventis : Risk Factors and Prevention Merck Sharp & Dohme : Risk Factors and Prevention</p> <p>Payment from healthcare industry to your department or institution or any other body for your personal services: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc., including travel funding related to these activities. Daiichi Sankyo : Risk Factors and Prevention Sanofi Aventis : Risk Factors and Prevention</p>
Kuperstein Rafael	<p>2023</p> <p>Nothing to be declared</p> <p>2024</p> <p>Nothing to be declared</p>
Landmesser Ulf	<p>2023</p> <p>Ongoing research funding from public and/or not-for-profit organisations (which started in 2023 or continues in 2023). This information is not mandatory and does not impact one's ability to join an ESC activity German Center of Cardiovascular Research (DZHK)</p> <p>Payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc., including travel funding related to these activities. Novartis : Coronary Artery Disease (Chronic) / Chronic Coronary Syndromes (CCS) Amgen : Risk Factors and Prevention Novartis : Risk Factors and Prevention Sanofi Aventis : Risk Factors and Prevention</p> <p>Research funding from healthcare industry received by your department/institution or an entity controlled by your department/institution , under your direct/personal responsibility. Abbott : EXAMINE-CAD Study, Principal Investigator Novartis : Support of clinical study to institution, Principal investigator</p>

2025 ESC Guidelines for the management of cardiovascular disease and pregnancy - Review panel

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2024.

Expert	Type of Relationship with Industry
Landmesser Ulf	<p>2024</p> <p>Ongoing research funding from public and/or not-for-profit organisations. This information is not mandatory and does not impact one's ability to join an ESC activity German Center of Cardiovascular Research (DZHK) Leducq Foundation - Network of excellence in cardiovascular research</p> <p>Payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc., including travel funding related to these activities. Menarini : Coronary Artery Disease (Chronic) / Chronic Coronary Syndromes (CCS) Amgen : Risk Factors and Prevention Novartis : Risk Factors and Prevention Sanofi Aventis : Risk Factors and Prevention</p> <p>Research funding from healthcare industry received by your department/institution or an entity controlled by your department/institution , under your direct/personal responsibility. Abbott : Clinical Study, Principal Investigator Merck Sharp & Dohme : Clinical Study, Steering Committee Novartis : Support of clinical study to institution, Principal investigator</p>
Laurila Sanna	<p>2023</p> <p>Payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc., including travel funding related to these activities. Boehringer-Ingelheim : Myocardial Disease Pfizer : Myocardial Disease</p> <p>Payment from healthcare industry to your department or institution or any other body for your personal services: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc., including travel funding related to these activities. Imbria Pharmaceuticals inc : Coronary Artery Disease (Chronic) / Chronic Coronary Syndromes (CCS) Bayer : Myocardial Disease</p> <p>Any other interest (financial or otherwise) that should be declared in view of holding an ESC position (e.g. editorial role in non-ESC publications—editor in chief or other editorial position—and/or officer position in other organisations). I will be editor-in-chief of the Finnish Cardiac Society's journal 'Sydänääni' from January 2024 onwards. Financial compensation is modest.</p>

2025 ESC Guidelines for the management of cardiovascular disease and pregnancy - Review panel

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2024.

Expert	Type of Relationship with Industry
Laurila Sanna	<p>2024</p> <p>Payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc., including travel funding related to these activities. Boehringer-Ingelheim : Myocardial Disease Pfizer : Myocardial Disease</p> <p>Payment from healthcare industry to your department or institution or any other body for your personal services: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc., including travel funding related to these activities. Bayer : Myocardial Disease</p> <p>Any other interest (financial or otherwise) that should be declared in view of holding an ESC position (e.g. editorial role in non-ESC publications—editor in chief or other editorial position—and/or officer position in other organisations). I was editor-in-chief of the Finnish Cardiac Society's journal 'Sydänääni' from January 2024 onwards. Financial compensation is modest.</p>
Leirgul Elisabeth	<p>2023</p> <p>Ongoing research funding from public and/or not-for-profit organisations (which started in 2023 or continues in 2023). This information is not mandatory and does not impact one's ability to join an ESC activity The Norwegian Association for Children with Congenital Heart Disease The Norwegian Women's Public Health Association</p> <p>2024</p> <p>Payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc., including travel funding related to these activities. W.L. Gore & associates : Clinical Skills, Training and Education</p> <p>Funding from healthcare industry for travel to, and attendance of events and meetings , unrelated to the activities listed in 2.A and 3.A. W.L. Gore & associates : Device Therapy</p>
Lip Gregory Yh	<p>2023</p> <p>Research funding from healthcare industry received by your department/institution or an entity controlled by your department/institution , under your direct/personal responsibility. Boehringer-Ingelheim : AF registries [unrestricted educational grant]. Academic, non promotional research work on registries by fellow., Principal Investigator Anthos : AF registries [unrestricted educational grant]. Academic, non promotional research work on registries by fellow., Principal Investigator</p> <p>Any other interest (financial or otherwise) that should be declared in view of holding an ESC position (e.g. editorial role in non-ESC publications—editor in chief or other editorial position—and/or officer position in other organisations). Shares in private limited company (a legal separate entity in UK), but no salary/income/personal remuneration received.</p>

2025 ESC Guidelines for the management of cardiovascular disease and pregnancy - Review panel

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2024.

Expert	Type of Relationship with Industry
Lip Gregory Yh	<p>2024</p> <p>Payment from healthcare industry to your department or institution or any other body for your personal services: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc., including travel funding related to these activities. Pfizer : Atrial Fibrillation (AF) Bristol Myers Squibb : Atrial Fibrillation (AF)</p> <p>Funding from healthcare industry for travel to, and attendance of events and meetings , unrelated to the activities listed in 2.A and 3.A. Daiichi Sankyo : Atrial Fibrillation (AF)</p> <p>Research funding from healthcare industry received by your department/institution or an entity controlled by your department/institution , under your direct/personal responsibility. Bristol Myers Squibb : AF 'real world' registry work. Academic, non promotional research work on registries , project supervision Boehringer-Ingelheim : AF registries [unrestricted educational grant]. Academic, non promotional research work on registries by fellows., project supervision Anthos : AF registries [unrestricted educational grant]. Academic, non promotional research work on registries by fellows., project supervision</p> <p>Any other interest (financial or otherwise) that should be declared in view of holding an ESC position (e.g. editorial role in non-ESC publications—editor in chief or other editorial position—and/or officer position in other organisations). Editorial roles in a number of academic journals. Shares in private limited company (a legal separate entity in UK), but no salary/income/personal remuneration received.</p>
Magavern Emma	<p>2023 Nothing to be declared</p> <p>2024 Nothing to be declared</p>
Maser Maarja	<p>2023 Nothing to be declared</p> <p>2024 Nothing to be declared</p>
Mcevoy John William	<p>2023 Nothing to be declared</p> <p>2024 Nothing to be declared</p>

2025 ESC Guidelines for the management of cardiovascular disease and pregnancy - Review panel

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2024.

Expert	Type of Relationship with Industry
Mihaylova Borislava	2023 Ongoing research funding from public and/or not-for-profit organisations (which started in 2023 or continues in 2023). This information is not mandatory and does not impact one's ability to join an ESC activity Barts Charity, UK Bowel Research UK Cancer Research UK National Institute for Health and Care Research, UK
	2024 Ongoing research funding from public and/or not-for-profit organisations. This information is not mandatory and does not impact one's ability to join an ESC activity Barts Charity, UK Bowel Research UK Cancer Research UK National Institute for Health and Care Research, UK
Mindham Richard	2023 Payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc., including travel funding related to these activities. NiCE (National Institute for Health & Care Excellence) - UK Government body. Guideline development.. Commences January 2024. : Chronic Heart Failure PASSpaces. http://passpaces.co.uk/ . PASSpaces tutors young British doctors to help them pass their medical examinations. I "act" as a patient, permitting the trainee to take a patient history. : Training and Education Funding from healthcare industry for travel to, and attendance of events and meetings , unrelated to the activities listed in 2.A and 3.A. European Society of Cardiology. Payment of hotel, travel and meals to attend or speak at ESC conferences. : European Society of Cardiology

2025 ESC Guidelines for the management of cardiovascular disease and pregnancy - Review panel

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2024.

Expert	Type of Relationship with Industry	
Mindham Richard	2023	<p>Membership or affiliation in political or advocacy groups working in the field of cardiology. I support the British charity CardiomyopathyUK, https://www.cardiomyopathy.org.uk/. I make small financial contributions to support their activities. I support the British charity Pumping Marvellous, https://pumpingmarvellous.org/. I make no financial contributions to the charity's activities. I am a member of the Coalition for Reducing Bureaucracy in Clinical Trials, https://bureaucracyincts.eu/. The Coalition is a collection of researchers, clinicians and patients which advocates for the reduction of bureaucracy in clinical trials, chiefly in the EU. I have no financial interest in the Coalition.</p> <p>Any other interest (financial or otherwise) that should be declared in view of holding an ESC position (e.g. editorial role in non-ESC publications—editor in chief or other editorial position—and/or officer position in other organisations). I have savings and pensions held in shares. The shares are managed by a financial adviser; I do not control the purchase & sale of shares and I do not know whether any shares are in medical companies.</p>
	2024	<p>Payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc., including travel funding related to these activities. National Institute for Health and Clinical Excellence : Chronic Heart Failure National Institute for Prevention and Cardiovascular Health (NIPC), Ireland : Rehabilitation and Sports Cardiology, Training and Education PASSpaces : Training and Education</p> <p>Membership or affiliation in political or advocacy groups working in the field of cardiovascular medicine. Cardiomyopathy UK, a British charity, registered with the government. I support the charity with donations. Heart Failure Warriors, a British charity, registered with the government. I have transferred all of the fees from NIPC (please see 2A) to HF Warriors.</p> <p>Any other interest (financial or otherwise) that should be declared in view of holding an ESC position (e.g. editorial role in non-ESC publications—editor in chief or other editorial position—and/or officer position in other organisations). Patient member of advisory board to two Horizon-funded programmes: RAPHAEL (investigating HF palliation) and More-EUROPA (investigating Real World Data in healthcare). I receive no payments from these programmes. Patient member of UK Digital, a UK study researching patients' expectations from digital technology. I receive no payment from UK Digital. I attended the kick-off event where my train fare, hotel bill and dinner were paid for by the study.</p>
Mitchenko Olena	2023	Nothing to be declared
	2024	Nothing to be declared
Moelgaard Inge	2023	Nothing to be declared
	2024	Nothing to be declared

2025 ESC Guidelines for the management of cardiovascular disease and pregnancy - Review panel

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2024.

Expert	Type of Relationship with Industry	
Moons Philip	2023	Payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc., including travel funding related to these activities. Pfizer : e-Cardiology/Digital Health
	2024	Nothing to be declared
Motovska Zuzana	2023	Payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc., including travel funding related to these activities. Idorsia : Acute Coronary Syndromes Boehringer-Ingelheim : Acute Heart Failure
	2024	Payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc., including travel funding related to these activities. Janssen-Cilag : Acute Coronary Syndromes Idorsia : Acute Coronary Syndromes TIMI group : Acute Heart Failure
Nielsen Jens Cosedis	2023	Nothing to be declared
	2024	Nothing to be declared
Ntusi Ntobeko Ayanda Bubele	2023	Payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc., including travel funding related to these activities. Servier : Hypertension Membership or affiliation in political or advocacy groups working in the field of cardiology. Advocacy Committee, Society for Cardiovascular Magnetic Resonance
	2024	Ongoing research funding from public and/or not-for-profit organisations. This information is not mandatory and does not impact one's ability to join an ESC activity US National Institutes of Health, South African Medical Research Council

2025 ESC Guidelines for the management of cardiovascular disease and pregnancy - Review panel

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2024.

Expert	Type of Relationship with Industry	
Pasquet Agnes A	2023	<p>Payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc., including travel funding related to these activities. Servier : Hypertension</p> <p>Payment from healthcare industry to your department or institution or any other body for your personal services: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc., including travel funding related to these activities. Servier : Hypertension</p> <p>Research funding from healthcare industry received by your department/institution or an entity controlled by your department/institution , under your direct/personal responsibility. Philips : echography, contribution and support</p>
	2024	<p>Payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc., including travel funding related to these activities. Servier : Hypertension</p> <p>Payment from healthcare industry to your department or institution or any other body for your personal services: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc., including travel funding related to these activities. Servier : Hypertension</p> <p>Research funding from healthcare industry received by your department/institution or an entity controlled by your department/institution , under your direct/personal responsibility. Philips : echography, contribution and support</p>
Pavo Noemi	2023	<p>Ongoing research funding from public and/or not-for-profit organisations (which started in 2023 or continues in 2023). This information is not mandatory and does not impact one's ability to join an ESC activity OeNB (Österreichische Nationalbank), HFA of Austria</p> <p>Membership or affiliation in political or advocacy groups working in the field of cardiology. Board member of the HFA of Austria</p>
	2024	<p>Ongoing research funding from public and/or not-for-profit organisations. This information is not mandatory and does not impact one's ability to join an ESC activity OeNB (Österreichische Nationalbank), HFA of Austria</p> <p>Membership or affiliation in political or advocacy groups working in the field of cardiovascular medicine. Board member of the HFA of Austria</p>

2025 ESC Guidelines for the management of cardiovascular disease and pregnancy - Review panel

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2024.

Expert	Type of Relationship with Industry
Pedreira Perez Milagros	2023 Ongoing research funding from public and/or not-for-profit organisations (which started in 2023 or continues in 2023). This information is not mandatory and does not impact one's ability to join an ESC activity Institut Carlos III.General Subdireccction of evaluation and promotion investigation. Mnistry of science and innovation .Spanish Goverment Payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc., including travel funding related to these activities. Organon : Coronary Artery Disease (Chronic) / Chronic Coronary Syndromes (CCS), Risk Factors and Prevention Funding from healthcare industry for travel to, and attendance of events and meetings , unrelated to the activities listed in 2.A and 3.A. Organon : Clinical Skills, Coronary Artery Disease (Chronic) / Chronic Coronary Syndromes (CCS)
	2024 Payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc., including travel funding related to these activities. Organon : Coronary Artery Disease (Chronic) / Chronic Coronary Syndromes (CCS), Risk Factors and Prevention Daiichi Sankyo : European Society of Cardiology Bayer : Training and Education
Potpara Tatjana	2023 Payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc., including travel funding related to these activities. Boston Scientific : Atrial Fibrillation (AF)
	2024 Nothing to be declared
Prescott Eva	2023 Nothing to be declared
	2024 Nothing to be declared
Prokselj Katja	2023 Payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc., including travel funding related to these activities. Johnson & Johnson : Pulmonary Circulation, Pulmonary Embolism, Right Heart Failure
	2024 Payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc., including travel funding related to these activities. Boehringer-Ingelheim : Congenital Heart Disease and Paediatric Cardiology Merck Sharp & Dohme : Congenital Heart Disease and Paediatric Cardiology Johnson & Johnson : Pulmonary Circulation, Pulmonary Embolism, Right Heart Failure

2025 ESC Guidelines for the management of cardiovascular disease and pregnancy - Review panel

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2024.

Expert	Type of Relationship with Industry
Rocca Bianca	<p>2023</p> <p>Ongoing research funding from public and/or not-for-profit organisations (which started in 2023 or continues in 2023). This information is not mandatory and does not impact one's ability to join an ESC activity Cancer UK</p> <p>Payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc., including travel funding related to these activities. Aboca, SRL : Other</p> <p>Any other interest (financial or otherwise) that should be declared in view of holding an ESC position (e.g. editorial role in non-ESC publications—editor in chief or other editorial position—and/or officer position in other organisations). Editorial Board of: Assistant Editor Diabetes and Vascular Disease Research Advisory Board: Pharmadvances. Associate Editor: Cardiovascular Drugs and Therapy, Clinical Pharmacology Editorial Board: Bleeding, Thrombosis, and Vascular Biology Associate Editor. Frontiers in Drug Safety and Regulation Section on Cardiovascular Drug Safety Associate Editor for European Cardiology Review Editorial Board European Journal of Preventive Cardiology Editorial Board Journal of Thrombosis and Thrombolysis Editorial Board International Journal of Cardiology</p>
	<p>2024</p> <p>Ongoing research funding from public and/or not-for-profit organisations. This information is not mandatory and does not impact one's ability to join an ESC activity Cancer UK</p> <p>Payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc., including travel funding related to these activities. Bayer AG : Pharmacology and Pharmacotherapy</p> <p>Research funding from healthcare industry received by your department/institution or an entity controlled by your department/institution , under your direct/personal responsibility. Bios Therapy : Substance Based medical devices in obesity, site investigator</p> <p>Membership or affiliation in political or advocacy groups working in the field of cardiovascular medicine. ISTH, Italian Society of Thrombosis and Haemostasis (SISTE), Italian Society of Pharmacology (SIF), Mediterranean League against Thrombosis</p>
Roos-Hesselink Jolien W	<p>2023</p> <p>Any other interest (financial or otherwise) that should be declared in view of holding an ESC position (e.g. editorial role in non-ESC publications—editor in chief or other editorial position—and/or officer position in other organisations). Managing-Director Dutch CardioVascular Alliance (DCVA)</p>
	<p>2024</p> <p>Any other interest (financial or otherwise) that should be declared in view of holding an ESC position (e.g. editorial role in non-ESC publications—editor in chief or other editorial position—and/or officer position in other organisations). Managing-Director Dutch CardioVascular Alliance (DCVA)</p>

2025 ESC Guidelines for the management of cardiovascular disease and pregnancy - Review panel

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2024.

Expert	Type of Relationship with Industry	
Rossello Francisco Javier	2023	Nothing to be declared
	2024	Any other interest (financial or otherwise) that should be declared in view of holding an ESC position (e.g. editorial role in non-ESC publications—editor in chief or other editorial position—and/or officer position in other organisations). Associate editor of Heart - https://heart.bmj.com/pages/editorial-board Associate Statistical Editor of Circulation: Cardiovascular Quality and Outcomes - https://www.ahajournals.org/circoutcomes/editorial-board
Saade Georges	2023	Nothing to be declared
	2024	Nothing to be declared
Sannino Anna	2023	Nothing to be declared
	2024	Nothing to be declared
Skoric Bosko	2023	Payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc., including travel funding related to these activities. Salveo : Acute Coronary Syndromes Berlin Chemie AG : Atrial Fibrillation (AF) Viatrix : Chronic Heart Failure Boehringer-Ingelheim : Chronic Heart Failure, Acute Heart Failure Teva Pharmaceutical Industries : Chronic Heart Failure, Acute Heart Failure Novo-Nordisk : Coronary Artery Disease (Chronic) / Chronic Coronary Syndromes (CCS) Takeda Pharmaceuticals : Other Payment from healthcare industry to your department or institution or any other body for your personal services: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc., including travel funding related to these activities. Teva Pharmaceutical Industries : Chronic Heart Failure, Acute Heart Failure, Other Medis Adria : Other

2025 ESC Guidelines for the management of cardiovascular disease and pregnancy - Review panel

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2024.

Expert	Type of Relationship with Industry
Skoric Bosko	<p>2024</p> <p>Payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc., including travel funding related to these activities. Salveo : Acute Coronary Syndromes Berlin Chemie AG : Atrial Fibrillation (AF) Menarini : Chronic Heart Failure Boehringer-Ingelheim : Chronic Heart Failure, Acute Heart Failure Teva Pharmaceutical Industries : Chronic Heart Failure, Acute Heart Failure Novo-Nordisk : Coronary Artery Disease (Chronic) / Chronic Coronary Syndromes (CCS) Takeda Pharmaceuticals : Other</p> <p>Payment from healthcare industry to your department or institution or any other body for your personal services: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc., including travel funding related to these activities. Bayer : Atrial Fibrillation (AF) Astra Zeneca : Chronic Heart Failure Teva Pharmaceutical Industries : Chronic Heart Failure, Acute Heart Failure, Other Astellas : Other Zentiva : Other Medis Adria : Other</p> <p>Funding from healthcare industry for travel to, and attendance of events and meetings , unrelated to the activities listed in 2.A and 3.A. Boehringer-Ingelheim : Atrial Fibrillation (AF)</p> <p>Research funding from healthcare industry received personally by you or an entity controlled by you. Medis Adria</p>
Sliwa Karen	<p>2023</p> <p>Ongoing research funding from public and/or not-for-profit organisations (which started in 2023 or continues in 2023). This information is not mandatory and does not impact one's ability to join an ESC activity Hippocrate Foundation</p> <hr/> <p>2024</p> <p>Ongoing research funding from public and/or not-for-profit organisations. This information is not mandatory and does not impact one's ability to join an ESC activity Hippocrate Foundation</p>

2025 ESC Guidelines for the management of cardiovascular disease and pregnancy - Review panel

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2024.

Expert	Type of Relationship with Industry
Sow Rouguiatou	2023 Funding from healthcare industry for travel to, and attendance of events and meetings , unrelated to the activities listed in 2.A and 3.A. Bayer Laboratory : Other
	2024 Payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc., including travel funding related to these activities. Astra Zeneca : Cardiovascular Disease in Special Populations Funding from healthcare industry for travel to, and attendance of events and meetings , unrelated to the activities listed in 2.A and 3.A. Bayer Laboratory : Other
Tanner Felix C	2023 Ongoing research funding from public and/or not-for-profit organisations (which started in 2023 or continues in 2023). This information is not mandatory and does not impact one's ability to join an ESC activity Swiss Heart Foundation Funding from healthcare industry for travel to, and attendance of events and meetings , unrelated to the activities listed in 2.A and 3.A. Philips : Echocardiography Any other interest (financial or otherwise) that should be declared in view of holding an ESC position (e.g. editorial role in non-ESC publications—editor in chief or other editorial position—and/or officer position in other organisations). Secretary, UEMS Cardiac Section Board, Swiss Institute for Medical Education Board, Swiss Heart Foundation Editorial Board, International Journal of Cardiology Editorial Board, Journal of Clinical Medicine Editorial Board, Swiss Medical Weekly Editorial Board, Cardiovascular Medicine
	2024 Ongoing research funding from public and/or not-for-profit organisations. This information is not mandatory and does not impact one's ability to join an ESC activity Swiss Heart Foundation Any other interest (financial or otherwise) that should be declared in view of holding an ESC position (e.g. editorial role in non-ESC publications—editor in chief or other editorial position—and/or officer position in other organisations). Secretary, UEMS Cardiac Section Board, Swiss Institute for Medical Education Board, Swiss Heart Foundation Editorial Board, International Journal of Cardiology Editorial Board, Journal of Clinical Medicine Editorial Board, Swiss Medical Weekly

2025 ESC Guidelines for the management of cardiovascular disease and pregnancy - Review panel

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2024.

Expert	Type of Relationship with Industry	
Trojnariska Olga	2023	Payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc., including travel funding related to these activities. Bausch Health : Echocardiography Sandoz : Echocardiography , Valvular Heart Disease , Congenital Heart Disease and Paediatric Cardiology , Cardiovascular Disease in Special Populations Astra Zeneca : Echocardiography, Valvular Heart Disease
	2024	Payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc., including travel funding related to these activities. Bausch Health : Echocardiography Sandoz : Echocardiography , Valvular Heart Disease , Congenital Heart Disease and Paediatric Cardiology , Cardiovascular Disease in Special Populations Astra Zeneca : Echocardiography, Valvular Heart Disease
Vaartjes Ilonca	2023	Nothing to be declared
	2024	Nothing to be declared
Vrints Christiaan J M	2023	Nothing to be declared
	2024	Nothing to be declared
Youssef Ghada	2023	Payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc., including travel funding related to these activities. OMRON Healthcare : Hypertension
	2024	Nothing to be declared
Zakirova Feruza	2023	Nothing to be declared
	2024	Nothing to be declared
Zavatta Marco	2023	Nothing to be declared
	2024	Nothing to be declared

2025 ESC Guidelines for the management of cardiovascular disease and pregnancy - Review panel

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2024.

Expert	Type of Relationship with Industry	
Zeppenfeld Katja	2023	Payment from healthcare industry to your department or institution or any other body for your personal services: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc., including travel funding related to these activities. Biosense Webster : Ventricular Arrhythmias and Sudden Cardiac Death (SCD) Research funding from healthcare industry received by your department/institution or an entity controlled by your department/institution , under your direct/personal responsibility. Biosense Webster : Investigator initiated research, ventricular arrhythmias, PI
	2024	Nothing to be declared
Zwaagman Dayenne Ilse	2023	Nothing to be declared
	2024	Nothing to be declared

Clinical Practice Guidelines Committee 2024-2026 - Members

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2024.

Expert	Type of Relationship with Industry	
Adamo Marianna	2023	<p>Payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc., including travel funding related to these activities. Edwards Lifesciences : Valvular Heart Disease Abbott Vascular : Valvular Heart Disease</p> <p>Total impact on personal income or income to an entity controlled personally <10,000EUR/year</p>
	2024	<p>Payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc., including travel funding related to these activities. Edwards Lifesciences : Valvular Heart Disease Abbott Vascular : Valvular Heart Disease</p> <p>Total impact on personal income or income to an entity controlled personally <10,000EUR/year</p>
Aktaa Suleman	2023	Nothing to be declared
	2024	Nothing to be declared
Asselbergs Folkert	2023	<p>Ongoing research funding from public and/or not-for-profit organisations (which started in 2023 or continues in 2023). This information is not mandatory and does not impact one's ability to join an ESC activity EU Horizon The Dutch Research Council (NWO) The Netherlands Organisation for Health Research and Development (ZonMw)</p> <p>Research funding from healthcare industry received by your department/institution or an entity controlled by your department/institution , under your direct/personal responsibility. Novartis : Implementation of common data model for heart failure care pathway , principal investigator Astra Zeneca : Nudging trial to improve guideline adherence in heart failure, principal investigator</p> <p>Total impact on personal income or income to an entity controlled personally <10,000EUR/year</p>

Clinical Practice Guidelines Committee 2024-2026 - Members

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2024.

Expert	Type of Relationship with Industry	
Asselbergs Folkert	2024	<p>Research funding from healthcare industry received by your department/institution or an entity controlled by your department/institution , under your direct/personal responsibility. Novartis : Data standardisation quality registry, principal investigator Astra Zeneca : Nudging trial to improve guideline adherence, principal investigator</p> <p>Total impact on personal income or income to an entity controlled personally <10,000EUR/year</p>
Baigent Colin	2023	<p>Ongoing research funding from public and/or not-for-profit organisations (which started in 2023 or continues in 2023). This information is not mandatory and does not impact one's ability to join an ESC activity UK Medical Research Council</p> <p>Research funding from healthcare industry received by your department/institution or an entity controlled by your department/institution , under your direct/personal responsibility. Boehringer-Ingelheim : Funding provided for the coordination of the EMPA-KIDNEY trial, Chair of Steering Committee</p> <p>Total impact on personal income or income to an entity controlled personally <10,000EUR/year</p>
	2024	<p>Ongoing research funding from public and/or not-for-profit organisations. This information is not mandatory and does not impact one's ability to join an ESC activity UK Medical Research Council</p> <p>Research funding from healthcare industry received by your department/institution or an entity controlled by your department/institution , under your direct/personal responsibility. Boehringer-Ingelheim : Funding provided for the coordination of the EMPA-KIDNEY and EASI-KIDNEY trials, Chair of Steering Committee</p> <p>Total impact on personal income or income to an entity controlled personally <10,000EUR/year</p>

Clinical Practice Guidelines Committee 2024-2026 - Members

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2024.

Expert	Type of Relationship with Industry	
Borger Michael A	2023	<p>Payment from healthcare industry to your department or institution or any other body for your personal services: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc., including travel funding related to these activities.</p> <p>Artivion (formerly CryoLife) : Diseases of the Aorta</p> <p>Abbott : Valvular Heart Disease</p> <p>Edwards Lifesciences : Valvular Heart Disease</p> <p>Medtronic : Valvular Heart Disease</p> <p>Total impact on personal income or income to an entity controlled personally <10,000EUR/year</p>
	2024	<p>Payment from healthcare industry to your department or institution or any other body for your personal services: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc., including travel funding related to these activities.</p> <p>Artivion (formerly CryoLife) : Diseases of the Aorta</p> <p>Abbott : Valvular Heart Disease</p> <p>Edwards Lifesciences : Valvular Heart Disease</p> <p>Medtronic : Valvular Heart Disease</p> <p>Total impact on personal income or income to an entity controlled personally <10,000EUR/year</p>
Boriani Giuseppe	2023	Nothing to be declared
	2024	<p>Payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc., including travel funding related to these activities.</p> <p>Bristol Myers Squibb : Arrhythmias, General</p> <p>Daiichi Sankyo : Atrial Fibrillation (AF)</p> <p>Boston Scientific : Ventricular Arrhythmias and Sudden Cardiac Death (SCD)</p>

Clinical Practice Guidelines Committee 2024-2026 - Members

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2024.

Expert	Type of Relationship with Industry	
Boriani Giuseppe	2024	<p>Any other interest (financial or otherwise) that should be declared in view of holding an ESC position (e.g. editorial role in non-ESC publications—editor in chief or other editorial position—and/or officer position in other organisations). Member of the Editorial Board of Acta Cardiologica and European Journal of Internal Medicine</p> <p>Total impact on personal income or income to an entity controlled personally <10,000EUR/year</p>
Brida Margarita	2023	Nothing to be declared
	2024	Nothing to be declared
Byrne Robert	2023	<p>Research funding from healthcare industry received by your department/institution or an entity controlled by your department/institution , under your direct/personal responsibility. Biosensors : Clinical trial activity, Principal investigator Abbott Vascular : Research/educational grant to institution of employment to support fellowship programme, Clinical director Boston Scientific : Research/educational grant to institution of employment to support fellowship programme, Principal investigator Translumina : Research/educational grant to institution of employment to support research nurse for patient outcomes, Principal investigator</p> <p>Membership or affiliation in political or advocacy groups working in the field of cardiology. Member of Irish Heart Attack Audit Governance Committee Member Health Products Regulatory Authority (HPRA; Irish Competent Authority) Advisory Committee on Medical Devices</p> <p>Any other interest (financial or otherwise) that should be declared in view of holding an ESC position (e.g. editorial role in non-ESC publications—editor in chief or other editorial position—and/or officer position in other organisations). Deputy Editor at EuroIntervention Guest Editor at Circulation</p> <p>Total impact on personal income or income to an entity controlled personally <10,000EUR/year</p>
	2024	<p>Research funding from healthcare industry received by your department/institution or an entity controlled by your department/institution , under your direct/personal responsibility. Biosensors : Clinical trial activity, Principal investigator Boston Scientific : Research grant to institution of employment to support a clinical trial, Principal investigator Abbott Vascular : Research/educational grant to institution of employment to support fellowship programme, Clinical director Translumina : Research/educational grant to institution of employment to support research nurse for patient outcomes, Clinical director</p>

Clinical Practice Guidelines Committee 2024-2026 - Members

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2024.

Expert	Type of Relationship with Industry
Byrne Robert	<p>2024</p> <p>Membership or affiliation in political or advocacy groups working in the field of cardiovascular medicine. Member of Irish Heart Attack Audit Governance Committee Member Health Products Regulatory Authority (HPRA; Irish Competent Authority) Advisory Committee on Medical Devices</p> <p>Any other interest (financial or otherwise) that should be declared in view of holding an ESC position (e.g. editorial role in non-ESC publications—editor in chief or other editorial position—and/or officer position in other organisations). Deputy Editor at EuroIntervention Guest Editor at Circulation</p> <p>Total impact on personal income or income to an entity controlled personally <10,000EUR/year</p>
Gandjbakhch Estelle	<p>2023</p> <p>Payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc., including travel funding related to these activities. Boston Scientific : Device Therapy Medtronic : Device Therapy Biotronik : Device Therapy Microport : Device Therapy Abbott : Interventional Cardiology</p> <p>Research funding from healthcare industry received by your department/institution or an entity controlled by your department/institution , under your direct/personal responsibility. Biotronik : research grant for academic research on inherited arrhythmia and catheter ablation, investigator Boston Scientific : research grant for academic research on inherited arrhythmia and catheter ablation, principal investigator Medtronic : research grant for academic research on inherited arrhythmia and catheter ablation, principal investigator Microport : research grant for academic research on inherited arrhythmia and catheter ablation, principal investigator</p> <p>Total impact on personal income or income to an entity controlled personally <10,000EUR/year</p>

Clinical Practice Guidelines Committee 2024-2026 - Members

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2024.

Expert	Type of Relationship with Industry
Gandjbakhch Estelle	<p>2024</p> <p>Payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc., including travel funding related to these activities. Boston Scientific : Device Therapy Medtronic : Device Therapy Biotronik : Device Therapy Zoll Medical : Device Therapy Microport : Device Therapy Abbott : Interventional Cardiology Tenaya : Myocardial Disease</p> <p>Research funding from healthcare industry received by your department/institution or an entity controlled by your department/institution , under your direct/personal responsibility. Biotronik : research grant for academic research on inherited arrhythmia and catheter ablation, investigator Boston Scientific : research grant for academic research on inherited arrhythmia and catheter ablation, principal investigator Medtronic : research grant for academic research on inherited arrhythmia and catheter ablation, principal investigator Microport : research grant for academic research on inherited arrhythmia and catheter ablation, principal investigator</p> <p>Total impact on personal income or income to an entity controlled personally <10,000EUR/year</p>
Heidecker Bettina	<p>2023</p> <p>Ongoing research funding from public and/or not-for-profit organisations (which started in 2023 or continues in 2023). This information is not mandatory and does not impact one's ability to join an ESC activity Pfizer</p> <p>Payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc., including travel funding related to these activities. Pfizer, Bayer, Sanofi-Aventis, Novartis, Astra Zeneca : Clinical Skills, Chronic Heart Failure, Acute Heart Failure, Myocardial Disease, Pericardial Disease</p> <p>Research funding from healthcare industry received by your department/institution or an entity controlled by your department/institution , under your direct/personal responsibility. Pfizer : Analysis of biomarkers in blood of patients with amyloidosis; assess risk for adverse cardiovascular events, Principal investigator</p> <p>Total impact on personal income or income to an entity controlled personally <10,000EUR/year</p>

Clinical Practice Guidelines Committee 2024-2026 - Members

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2024.

Expert	Type of Relationship with Industry
Heidecker Bettina	<p>2024</p> <p>Ongoing research funding from public and/or not-for-profit organisations. This information is not mandatory and does not impact one's ability to join an ESC activity Pfizer</p> <p>Payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc., including travel funding related to these activities. Pfizer, Bayer, Sanofi-Aventis, Novartis, Astra Zeneca : Clinical Skills , Chronic Heart Failure , Acute Heart Failure , Myocardial Disease , Pericardial Disease</p> <p>Research funding from healthcare industry received by your department/institution or an entity controlled by your department/institution , under your direct/personal responsibility. Pfizer : Analysis of biomarkers in blood of patients with amyloidosis; assess risk for adverse cardiovascular events, Principal investigator</p> <p>Total impact on personal income or income to an entity controlled personally <10,000EUR/year</p>
Hennemuth Anja	<p>2023</p> <p>Ongoing research funding from public and/or not-for-profit organisations (which started in 2023 or continues in 2023). This information is not mandatory and does not impact one's ability to join an ESC activity BMBF Deutsche Forschungsgemeinschaft</p> <p>Total impact on personal income or income to an entity controlled personally <10,000EUR/year</p>
	<p>2024</p> <p>Ongoing research funding from public and/or not-for-profit organisations. This information is not mandatory and does not impact one's ability to join an ESC activity BMBF Deutsche Forschungsgemeinschaft</p> <p>Total impact on personal income or income to an entity controlled personally <10,000EUR/year</p>

Clinical Practice Guidelines Committee 2024-2026 - Members

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2024.

Expert	Type of Relationship with Industry
Ibanez Borja	<p>2023</p> <p>Any other interest (financial or otherwise) that should be declared in view of holding an ESC position (e.g. editorial role in non-ESC publications—editor in chief or other editorial position—and/or officer position in other organisations). My center (CNIC) is a public non-profit institution that receives Royalties for the sale of a polypill containing aspirin, ramipril and atorvastatin (trinomia, sincronium). I am not involved in the development I do NOT receive any personal benefit (neither direct nor indirect).</p> <p>Total impact on personal income or income to an entity controlled personally <10,000EUR/year</p> <hr/> <p>2024</p> <p>Any other interest (financial or otherwise) that should be declared in view of holding an ESC position (e.g. editorial role in non-ESC publications—editor in chief or other editorial position—and/or officer position in other organisations). My center (CNIC) is a public non-profit institution that receives Royalties for the sale of a polypill containing aspirin, ramipril and atorvastatin (trinomia, sincronium). I am not involved in the development I do NOT receive any personal benefit (neither direct nor indirect).</p> <p>Total impact on personal income or income to an entity controlled personally <10,000EUR/year</p>
James Stefan	<p>2023</p> <p>Ongoing research funding from public and/or not-for-profit organisations (which started in 2023 or continues in 2023). This information is not mandatory and does not impact one's ability to join an ESC activity Wallenberg foundation, Swedish heart and lung foundation</p> <p>Payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc., including travel funding related to these activities. Medtronic : Valvular Heart Disease</p> <p>Research funding from healthcare industry received by your department/institution or an entity controlled by your department/institution , under your direct/personal responsibility. Elixir : clinical trial, study chair MSD : Clinical trial, trial executive committee Amgen : Executive committee member, Executive committee member Janssen-Cilag : Executive committee member, Executive committee member Astra Zeneca : Study PI , Principal investigator</p>

Clinical Practice Guidelines Committee 2024-2026 - Members

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2024.

Expert	Type of Relationship with Industry	
James Stefan	2023	<p>Membership or affiliation in political or advocacy groups working in the field of cardiology. Swedish medical Association, Swedish cardiac society</p> <p>Total impact on personal income or income to an entity controlled personally <10,000EUR/year</p>
	2024	<p>Ongoing research funding from public and/or not-for-profit organisations. This information is not mandatory and does not impact one's ability to join an ESC activity Swedish research council</p> <p>Payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc., including travel funding related to these activities. Edwards Lifesciences : Valvular Heart Disease Medtronic : Valvular Heart Disease</p> <p>Research funding from healthcare industry received by your department/institution or an entity controlled by your department/institution , under your direct/personal responsibility. Amgen Inc : Clinical trial, Executive committee Merck Sharp & Dohme : Clinical trial, Executive committee New Amsterdam : DSMB committee. Lipid management , DSMB committee Janssen-Cilag : Executive committee, Executive committee</p> <p>Membership or affiliation in political or advocacy groups working in the field of cardiovascular medicine. Board member of the Swedish research council</p> <p>Total impact on personal income or income to an entity controlled personally <10,000EUR/year</p>
Juni Peter	2023	Nothing to be declared
	2024	Nothing to be declared

Clinical Practice Guidelines Committee 2024-2026 - Members

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2024.

Expert	Type of Relationship with Industry
Landmesser Ulf	<p>2023</p> <p>Ongoing research funding from public and/or not-for-profit organisations (which started in 2023 or continues in 2023). This information is not mandatory and does not impact one's ability to join an ESC activity German Center of Cardiovascular Research (DZHK)</p> <p>Payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc., including travel funding related to these activities. Novartis : Coronary Artery Disease (Chronic) / Chronic Coronary Syndromes (CCS) Amgen : Risk Factors and Prevention Novartis : Risk Factors and Prevention Sanofi Aventis : Risk Factors and Prevention</p> <p>Research funding from healthcare industry received by your department/institution or an entity controlled by your department/institution , under your direct/personal responsibility. Abbott : EXAMINE-CAD Study, Principal Investigator Novartis : Support of clinical study to institution, Principal investigator</p> <p>Total impact on personal income or income to an entity controlled personally <10,000EUR/year</p>

Clinical Practice Guidelines Committee 2024-2026 - Members

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2024.

Expert	Type of Relationship with Industry
Landmesser Ulf	<p>2024</p> <p>Ongoing research funding from public and/or not-for-profit organisations. This information is not mandatory and does not impact one's ability to join an ESC activity German Center of Cardiovascular Research (DZHK) Leducq Foundation - Network of excellence in cardiovascular research</p> <p>Payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc., including travel funding related to these activities. Menarini : Coronary Artery Disease (Chronic) / Chronic Coronary Syndromes (CCS) Amgen : Risk Factors and Prevention Novartis : Risk Factors and Prevention Sanofi Aventis : Risk Factors and Prevention</p> <p>Research funding from healthcare industry received by your department/institution or an entity controlled by your department/institution , under your direct/personal responsibility. Abbott : Clinical Study, Principal Investigator Merck Sharp & Dohme : Clinical Study, Steering Committee Novartis : Support of clinical study to institution, Principal investigator</p> <p>Total impact on personal income or income to an entity controlled personally <10,000EUR/year</p>
Lip Gregory Yh	<p>2023</p> <p>Research funding from healthcare industry received by your department/institution or an entity controlled by your department/institution , under your direct/personal responsibility. Boehringer-Ingelheim : AF registries [unrestricted educational grant]. Academic, non promotional research work on registries by fellow., Principal Investigator Anthos : AF registries [unrestricted educational grant]. Academic, non promotional research work on registries by fellow., Principal Investigator</p> <p>Any other interest (financial or otherwise) that should be declared in view of holding an ESC position (e.g. editorial role in non-ESC publications—editor in chief or other editorial position—and/or officer position in other organisations). Shares in private limited company (a legal separate entity in UK), but no salary/income/personal remuneration received.</p> <p>Total impact on personal income or income to an entity controlled personally <10,000EUR/year</p>

Clinical Practice Guidelines Committee 2024-2026 - Members

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2024.

Expert	Type of Relationship with Industry
Lip Gregory Yh	<p>2024</p> <p>Payment from healthcare industry to your department or institution or any other body for your personal services: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc., including travel funding related to these activities. Pfizer : Atrial Fibrillation (AF) Bristol Myers Squibb : Atrial Fibrillation (AF)</p> <p>Funding from healthcare industry for travel to, and attendance of events and meetings , unrelated to the activities listed in 2.A and 3.A. Daiichi Sankyo : Atrial Fibrillation (AF)</p> <p>Research funding from healthcare industry received by your department/institution or an entity controlled by your department/institution , under your direct/personal responsibility. Bristol Myers Squibb : AF 'real world' registry work. Academic, non promotional research work on registries , project supervision Boehringer-Ingelheim : AF registries [unrestricted educational grant]. Academic, non promotional research work on registries by fellows., project supervision Anthos : AF registries [unrestricted educational grant]. Academic, non promotional research work on registries by fellows., project supervision</p> <p>Any other interest (financial or otherwise) that should be declared in view of holding an ESC position (e.g. editorial role in non-ESC publications—editor in chief or other editorial position—and/or officer position in other organisations). Editorial roles in a number of academic journals. Shares in private limited company (a legal separate entity in UK), but no salary/income/personal remuneration received.</p> <p>Total impact on personal income or income to an entity controlled personally <10,000EUR/year</p>
Mcevoy John William	<p>2023</p> <p>Nothing to be declared</p> <p>2024</p> <p>Nothing to be declared</p>
Mihaylova Borislava	<p>2023</p> <p>Ongoing research funding from public and/or not-for-profit organisations (which started in 2023 or continues in 2023). This information is not mandatory and does not impact one's ability to join an ESC activity Barts Charity, UK Bowel Research UK Cancer Research UK National Institute for Health and Care Research, UK</p>

Clinical Practice Guidelines Committee 2024-2026 - Members

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2024.

Expert	Type of Relationship with Industry
Mihaylova Borislava	2023 Total impact on personal income or income to an entity controlled personally <10,000EUR/year
	2024 Ongoing research funding from public and/or not-for-profit organisations. This information is not mandatory and does not impact one's ability to join an ESC activity Barts Charity, UK Bowel Research UK Cancer Research UK National Institute for Health and Care Research, UK Total impact on personal income or income to an entity controlled personally <10,000EUR/year
Moelgaard Inge	2023 Nothing to be declared
	2024 Nothing to be declared
Neubeck Lis	2023 Ongoing research funding from public and/or not-for-profit organisations (which started in 2023 or continues in 2023). This information is not mandatory and does not impact one's ability to join an ESC activity Burdett Trust for Nursing Chief Scientists Office Payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc., including travel funding related to these activities. Sanofi Aventis : Risk Factors and Prevention Research funding from healthcare industry received by your department/institution or an entity controlled by your department/institution , under your direct/personal responsibility. Daiichi Sankyo : Atrial fibrillation screening, Principal Investigator Any other interest (financial or otherwise) that should be declared in view of holding an ESC position (e.g. editorial role in non-ESC publications—editor in chief or other editorial position—and/or officer position in other organisations). Consultant Editor British Journal of Cardiac Nursing Total impact on personal income or income to an entity controlled personally <10,000EUR/year

Clinical Practice Guidelines Committee 2024-2026 - Members

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2024.

Expert	Type of Relationship with Industry	
Neubeck Lis	2024	<p>Ongoing research funding from public and/or not-for-profit organisations. This information is not mandatory and does not impact one's ability to join an ESC activity Burdett Trust for Nursing Chief Scientists Office</p> <p>Any other interest (financial or otherwise) that should be declared in view of holding an ESC position (e.g. editorial role in non-ESC publications—editor in chief or other editorial position—and/or officer position in other organisations). Consultant Editor British Journal of Cardiac Nursing</p> <p>Total impact on personal income or income to an entity controlled personally <10,000EUR/year</p>
Prescott Eva	2023	Nothing to be declared
	2024	Nothing to be declared
Rocca Bianca	2023	<p>Ongoing research funding from public and/or not-for-profit organisations (which started in 2023 or continues in 2023). This information is not mandatory and does not impact one's ability to join an ESC activity Cancer UK</p> <p>Payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc., including travel funding related to these activities. Aboca, SRL : Other</p> <p>Any other interest (financial or otherwise) that should be declared in view of holding an ESC position (e.g. editorial role in non-ESC publications—editor in chief or other editorial position—and/or officer position in other organisations). Editorial Board of: Assistant Editor Diabetes and Vascular Disease Research Advisory Board: Pharmadvances. Associate Editor: Cardiovascular Drugs and Therapy, Clinical Pharmacology Editorial Board: Bleeding, Thrombosis, and Vascular Biology Associate Editor. Frontiers in Drug Safety and Regulation Section on Cardiovascular Drug Safety Associate Editor for European Cardiology Review Editorial Board European Journal of Preventive Cardiology Editorial Board Journal of Thrombosis and Thrombolysis Editorial Board International Journal of Cardiology</p> <p>Total impact on personal income or income to an entity controlled personally <10,000EUR/year</p>

Clinical Practice Guidelines Committee 2024-2026 - Members

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2024.

Expert	Type of Relationship with Industry
Rocca Bianca	<p>2024</p> <p>Ongoing research funding from public and/or not-for-profit organisations. This information is not mandatory and does not impact one's ability to join an ESC activity Cancer UK</p> <p>Payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc., including travel funding related to these activities. Bayer AG : Pharmacology and Pharmacotherapy</p> <p>Research funding from healthcare industry received by your department/institution or an entity controlled by your department/institution , under your direct/personal responsibility. Bios Therapy : Substance Based medical devices in obesity, site investigator</p> <p>Membership or affiliation in political or advocacy groups working in the field of cardiovascular medicine. ISTH, Italian Society of Thrombosis and Haemostasis (SISST), Italian Society of Pharmacology (SIF), Mediterranean League against Thrombosis</p> <p>Total impact on personal income or income to an entity controlled personally <10,000EUR/year</p>
Rossello Francisco Javier	<p>2023</p> <p>Nothing to be declared</p> <hr/> <p>2024</p> <p>Any other interest (financial or otherwise) that should be declared in view of holding an ESC position (e.g. editorial role in non-ESC publications—editor in chief or other editorial position—and/or officer position in other organisations). Associate editor of Heart - https://heart.bmj.com/pages/editorial-board Associate Statistical Editor of Circulation: Cardiovascular Quality and Outcomes - https://www.ahajournals.org/circoutcomes/editorial-board</p> <p>Total impact on personal income or income to an entity controlled personally <10,000EUR/year</p>
Sannino Anna	<p>2023</p> <p>Nothing to be declared</p> <hr/> <p>2024</p> <p>Nothing to be declared</p>
Tanner Felix C	<p>2023</p> <p>Ongoing research funding from public and/or not-for-profit organisations (which started in 2023 or continues in 2023). This information is not mandatory and does not impact one's ability to join an ESC activity Swiss Heart Foundation</p> <p>Funding from healthcare industry for travel to, and attendance of events and meetings , unrelated to the activities listed in 2.A and 3.A. Philips : Echocardiography</p>

Clinical Practice Guidelines Committee 2024-2026 - Members

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2024.

Expert	Type of Relationship with Industry
Tanner Felix C	<p>2023</p> <p>Any other interest (financial or otherwise) that should be declared in view of holding an ESC position (e.g. editorial role in non-ESC publications—editor in chief or other editorial position—and/or officer position in other organisations). Secretary, UEMS Cardiac Section Board, Swiss Institute for Medical Education Board, Swiss Heart Foundation Editorial Board, International Journal of Cardiology Editorial Board, Journal of Clinical Medicine Editorial Board, Swiss Medical Weekly Editorial Board, Cardiovascular Medicine</p> <p>Total impact on personal income or income to an entity controlled personally <10,000EUR/year</p>
	<p>2024</p> <p>Ongoing research funding from public and/or not-for-profit organisations. This information is not mandatory and does not impact one's ability to join an ESC activity Swiss Heart Foundation</p> <p>Any other interest (financial or otherwise) that should be declared in view of holding an ESC position (e.g. editorial role in non-ESC publications—editor in chief or other editorial position—and/or officer position in other organisations). Secretary, UEMS Cardiac Section Board, Swiss Institute for Medical Education Board, Swiss Heart Foundation Editorial Board, International Journal of Cardiology Editorial Board, Journal of Clinical Medicine Editorial Board, Swiss Medical Weekly</p> <p>Total impact on personal income or income to an entity controlled personally <10,000EUR/year</p>
Wojakowski Wojciech	<p>2023</p> <p>Payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc., including travel funding related to these activities. Boehringer Ingelheim : Chronic Heart Failure Boehringer-Ingelheim : Chronic Heart Failure, Stroke Abbott Vascular : Coronary Artery Disease (Chronic) / Chronic Coronary Syndromes (CCS), Valvular Heart Disease Bristol Myers Squibb : Myocardial Disease Pfizer : Stroke</p> <p>Total impact on personal income or income to an entity controlled personally <10,000EUR/year</p>

Clinical Practice Guidelines Committee 2024-2026 - Members

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2024.

Expert	Type of Relationship with Industry	
Wojakowski Wojciech	2024	<p>Payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc., including travel funding related to these activities. Boehringer Ingelheim : Chronic Heart Failure Abbott Vascular : Coronary Artery Disease (Chronic) / Chronic Coronary Syndromes (CCS), Valvular Heart Disease Medtronic : Hypertension Bristol Myers Squibb : Myocardial Disease CroiValve : Valvular Heart Disease</p> <p>Total impact on personal income or income to an entity controlled personally <10,000EUR/year</p>
Zeppenfeld Katja	2023	<p>Payment from healthcare industry to your department or institution or any other body for your personal services: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc., including travel funding related to these activities. Biosense Webster : Ventricular Arrhythmias and Sudden Cardiac Death (SCD)</p> <p>Research funding from healthcare industry received by your department/institution or an entity controlled by your department/institution , under your direct/personal responsibility. Biosense Webster : Investigator initiated research, ventricular arrhythmias, PI</p> <p>Total impact on personal income or income to an entity controlled personally <10,000EUR/year</p>
	2024	Nothing to be declared